Excellent postdoctoral fellow in Neuro-Oncology (f/m/d)

The Hertie Institute for Clinical Brain Research (HIH), together with the University of Tübingen’s Neurology Hospital, forms the Center of Neurology. It is dedicated to research, treatment, and teaching focused on the diseases of the human brain.

We are announcing an open position for an

**excellent postdoctoral fellow in Neuro-Oncology**

**Summary of advertised position**

The Cluster of Excellence 2180 "Image-guided and Functionally Instructed Tumor Therapies" (iFIT) at the Eberhard Karls University Tübingen is the only oncology cluster of excellence in Germany. Since 01 January 2019, internationally renowned scientists and talented early career researchers have been working together in a globally unique collaboration of three different research areas to develop new, individualized cancer therapies.

Within the iFIT Cluster, the Department of Neuroscience and Interdisciplinary Neuro-Oncology at the Hertie-Institut for Clinical Brain Research and at the University Hospital Tübingen will recruit an excellent early career postdoctoral researcher. The scientific projects of the Department address the biology of tumors of the central nervous system, molecular mechanisms of acquired resistance to therapy, development of innovative novel therapeutic strategies and early phase clinical trials. We work together in a young, collaborative, dynamic and highly motivated team. We provide excellent supporting structures, access to state-of-the-art equipment and services through all Core Facilities. The successful applicant will benefit from the entire attractive interdisciplinary environment of the whole Tübingen Research Campus and Cyber Valley Health. Moreover, the candidate will receive dedicated mentoring and full support for empowerment towards next career steps.

**Essential job duties and responsibilities**

We accept applications from outstanding, highly motivated, collaborative and committed team players with a PhD/doctoral degree and a successfully completed first post-doctoral fellowship in a relevant area of molecular (neuro)oncology, preferably in metabolism and/or cell-based therapies and the iFIT scientific priority areas functional genomics and immunotherapy.

Applicants shall aim for an academic career and provide a track record of scientific excellence (first author publications in high ranking journals in the respective research area, postdoctoral fellowships at excellent institutions, competitive funding acquisition, successful supervision of students). We will provide successful candidates with a strong and competitive research program to get started as a postdoctoral researcher in Tübingen. Then, we will provide full support for external grant submissions for junior research group funding programs for establishing their junior research group in the Department of Neurology and Interdisciplinary Neuro-Oncology in Tübingen.

**Education and experience requirements**

- Team spirit and a collaborative mindset
- Excellent scientific track record
- Excellent scientific/technical skillset, preferably including practical experience in in vivo work
- Strong analytical and problem-solving skills
- Very good scientific writing skills
- A university degree and a PhD and strong background in natural and medical science with excellent degrees in biochemical or life sciences
- Very good English skills

The application should be within one pdf document and include: letter of motivation, summary of current and previous scientific work, curriculum vitae, certificate of transcripts, names of two references, pdf of first author publications.

**For questions, please contact**

Prof. Dr. Dr. Ghazaleh Tabatabai
Tel.: +49(0)7071 29-85018
E-Mail: ghazaleh.tabatabai@uni-tuebingen.de

**Address of institution**

Prof. Dr. Dr. Ghazaleh Tabatabai
Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen and Hertie Institute for Clinical Brain Research
Hoppe-Seyler-Strasse 3
72076 Tübingen, Germany

The position will be open until a convincing candidate has been identified.